Amelioration of graft ischemia-reperfusion injury by breviscapine in rat small bowel transplantation.
We sought to evaluate the effects of breviscapine to ameliorate graft ischemia-reperfusion (I/R) injury in a rat small bowel transplantation model. Thirty-six recipients were randomly divided into three groups (n = 12): operative controls, in which grafts were implanted immediately after harvesting; an I/R control group with grafts preserved in cold lactated Ringer's solution at 4 degrees C for 4 hours before transplantation; and a breviscapine group wherein the graft was treated in the same way as the I/R control group but breviscapine (25 mg/kg/d) was injected intraperitoneally into both the donors and the recipients for 3 days before the operation of and into the recipients after transplantation. We compared the pathological scores for I/R injury, apoptosis index, and content of malondialdehyde (MDA) in the graft. Breviscapine diminished the pathological change caused by I/R injury (breviscapine vs I/R control on 24 hours after operation, 1.50 +/- 0.55 vs 2.17 +/- 0.75; P < .05), decreased the apoptotic index (breviscapine vs I/R control at 24 hours after operation, 27.33 +/- 0.167 vs 73.83 +/- 0.077; P < .05), and reduced the graft tissue content of MDA (breviscapine vs I/R control on 24 hours after operation, 1.717 +/- 0.131 vs 3.167 +/- 0.196; P < .05). Breviscapine may protect the transplanted small intestine against I/R injury during transplantation in rats.